Assessment, Pretreatment and Treatment of Pharmaceutical Production Wastewaters in the Roche Group

Authors

  • Jürg Oliver Straub F.Hoffmann-La Roche Ltd, Group SHE (LSR), CH–4070 Basle, Switzerland; ERA Competence, Carmenstrasse 14, CH–4123 Allschwil, Switzerland;, Email: era.dr.j.o.straub@gmail.com
  • Christoph Acklin F.Hoffmann-La Roche AG, Site SHE (MSU), CH–4070 Basle, Switzerland
  • Jürgen Klemmer Roche Diagnostics GmbH, Wastewater Treatment, Nonnenwald 2, D–82377 Penzberg, Germany;
  • Marco Aurélio Kurlbaum Produtos Roche Químicos e Farmacêuticos S. A., Site SHE, Estrada dos Bandeirantes 2020, Jacarepaguá, Rio de Janeiro 22775-109, Brazil
  • Bin Li Shanghai Roche Pharmaceuticals Ltd, Site SHE, 1100 Long Dong Avenue, Pudong, Shanghai 201203, People's Republic of China
  • Martin studer F.Hoffmann-La Roche AG, Site SHE (MSU), CH–4070 Basle, Switzerland
  • Roland Zurbrügg F.Hoffmann-La Roche AG, Site SHE (MSU), CH–4070 Basle, Switzerland
  • Andreas Häner F.Hoffmann-La Roche Ltd, Group SHE (LSR), CH–4070 Basle, Switzerland;, Email: andreas.haener.ah1@roche.com

DOI:

https://doi.org/10.2533/chimia.2020.161

PMID:

32197675

Keywords:

Assessment, Management, Pharmaceuticals, Pretreatment, Production, Treatment, Wastewater

Abstract

The manufacturing of pharmaceuticals also produces wastes, mainly wastewaters (WWs). These WWs must be responsibly managed. Sometimes, the organic contents of these WWs are not easily removable in standard WW treatment, hence technical options must be investigated to pretreat such WWs in order to remove or destroy the recalcitrant compounds, mostly the active pharmaceutical ingredients themselves. This contribution from a pharmaceuticals company describes WW assessment and management principles, the search for pretreatment options and several case studies on WW (pre)treatment at some pharma production sites of the Roche Group.

Downloads

Published

2020-03-25